SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is trending after a strong earnings report, particularly driven by growth in its cloud computing unit, AWS. The community is actively discussing potential price targets and whether the stock will finally break out after lagging behind its peers this year. Some are attributing the surge to AI investments and anticipating analyst upgrades.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy Inc is trending amid discussions about its Q3 earnings, which beat analyst expectations. The community is focused on the company's large Bitcoin holdings and how this impacts MSTR's stock price relative to Bitcoin itself, with some analysts upgrading price targets. There's also debate around the company's business model and whether it offers a better investment than direct Bitcoin ownership.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple's earnings are driving discussions, with initial reactions mixed as the company beat overall expectations, but missed on iPhone revenue. Community members are focused on forward guidance, particularly a strong forecast for the December quarter, and debating whether the current valuation is justified. Bullish sentiment is fueled by potential upgrades and a possible short squeeze, while bears point to slowing growth and high P/E ratios.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid speculation of a potential bidding war, fueled by interest from major players like Netflix and Comcast, with reports suggesting a rejected offer from Paramount Skydance. The community is focused on potential takeover prices and deal structures, with some suggesting a higher valuation is warranted given WBD's assets, while regulatory hurdles for potential buyers are also being considered.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit's earnings have sparked lively discussions, with revenue and EPS exceeding expectations. The community is focused on the potential impact of AI and data licensing deals, along with the possibility of analyst upgrades and a short squeeze. Some traders are expressing concerns around competition and ad revenue, while others see significant long-term growth potential.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies is trending as investors discuss its potential for a short squeeze and anticipate upcoming earnings results. Community members are weighing in on the stock's high short interest and the potential impact of future interest rate cuts on the housing market and refinance activity. Bullish sentiment seems to be building around the company's long-term prospects, especially with the integration of recent acquisitions.

Solid Power, Inc. engages in the manufacture and supply of power batteries. The firm develops all solid state battery cell technology that replaces the liquid or gel polymer electrolyte used in conventional lithium-ion battery cells with a sulfide-based solid electrolyte. It focuses on the development and commercialization of all solid state battery cells and solid electrolyte materials, primarily for the battery-powered electric vehicle market. The company was founded on August 3, 2011 and is headquartered in Louisville, CO.

Solid Power Inc

Solid Power Inc - Ordinary Shares - Class A

Solid Power ($SLDP) is trending following news of a joint evaluation agreement with Samsung SDI and BMW to advance all-solid-state battery tech, sparking excitement about potential commercialization. The community is discussing the implications of this partnership, with some seeing it as a positive step while others express concerns about the timeline for tangible results. Broader discussions include the progress of solid-state battery technology and its potential impact on the EV sector.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is trending due to recent news and community speculation, particularly around its APU technology and a significant investment. The community is discussing potential acquisitions, partnerships with major players like NVDA, and the impact of government contracts. Investors are also focused on the company's upcoming earnings report and future guidance.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

Recent reports alleging safety issues with Dexcom's G7 device, including inaccurate readings leading to hospitalizations and deaths, have sparked concern and driven discussion about product quality and potential liabilities. The community is also closely watching for the company's response to these allegations and the potential impact on Dexcom's market position amid competition. Some believe the dip is an overreaction and a buying opportunity, anticipating a strong rebound with upcoming product releases.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors discuss the company's Q3 earnings, which revealed strong IBSRELA revenue growth and increased guidance. The community is optimistic about the company's near break-even status and potential for pipeline expansion, viewing it as an undervalued growth story. Discussion centers on the impact of these factors on the stock's momentum and future valuation, especially with a new NHE3 inhibitor in development.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Shares of Emergent BioSolutions jumped 18% in after-hours trading after the company posted stronger-than-expected Q3 results and raised its full-year guidance.</li><li>The quarter saw double-digit revenue growth led by Narcan and smallpox vaccine sales, along with margin gains and lower operating costs.</li><li>On Stocktwits, retail traders turned upbeat, with some predicting further upside in the coming sessions.</li></ul>Emergent BioSolutions shares rallied 18% in after-hours trading on Wednesday, sparking a wave of retail chatter on Thursday. The biotech firm surprised Wall Street with better-than-expected third-quarter (Q3) results, raised its 2025 outlook, and showed real traction across its naloxone and biodefense product lines.<h2 class="st-heading-2">Revenue Tops Forecast, Margins Improve</h2>Emergent delivered Q3 revenue of $231 million, up 10% from last year and ahead of guidance, helped by strong sales of its Narcan nasal spray and new government contracts for smallpox and anthrax countermeasures. Gross margin improved to 57%, while the company held costs in check, and operating expenses fell 41% from a year ago.Net income came in at $51 million, a big turnaround from last year’s losses, as Emergent’s restructuring efforts and product mix paid off. The company also reduced its net debt by nearly 20% and ended the quarter with $346 million in liquidity, including $246 million in cash.The company raised full-year revenue guidance to $775–$835 million and lifted adjusted EBITDA expectations to $195–$210 million, citing solid execution and international demand.<h2 class="st-heading-2">Smallpox Demand Drives Upside</h2>Emergent said its Narcan and Kloxxado products continue to lead the naloxone market, benefiting from stable U.S. pricing and growing over-the-counter availability. Meanwhile, international sales made up 34% of total medical countermeasure revenue and are proving more profitable than U.S. contracts.Sales of the company’s smallpox vaccine climbed 15% year over year, supported by long-term global supply deals. Emergent also highlighted progress on its partnership with Switzerland’s Rocketvax, with the first clinical trial for a next-generation vaccine platform expected to start in early 2026.<h2 class="st-heading-2">Stocktwits Traders See More Upside Ahead</h2>On Stocktwits, retail sentiment for Emergent BioSolutions shifted to ‘extremely bullish’ from ‘neutral’ a day ago amid a 289% jump in 24-hour message volume.&nbsp;One user predicted that Emergent BioSolutions’ stock could open around $20 or higher, saying they wouldn’t be surprised by a sharp move up.<stembedurl>https://stocktwits.com/angelburgosg/message/634258031</stembedurl>Another commenter said they viewed Emergent as a $30 stock, even without a potential buyout, adding that short sellers might soon be forced to cover.<stembedurl>https://stocktwits.com/Kawasaki1/message/634257787</stembedurl><a href="https://stocktwits.com/symbol/EBS">Emergent BioSolutions’ stock</a> has declined 2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The exterior view of the Emergent BioSolutions plant on April 01, 2021 in Baltimore, Maryland. (Photo by Tasos Katopodis/Getty Images)

Retail Traders Turn Ultra-Bullish On Emergent BioSolutions After Surprise Q3 Profit

Shares of Emergent BioSolutions jumped 18% in after-hours trading after the company posted stronger-than-expected Q3 results and raised its full-year guidance.

Equity

Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of +983.33% and +20.88%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

After a low period, biotech stocks are on the upswing, experts say

After a period of weakness, biotech stocks are on the upswing, experts say. But bear in mind: Putting your money into biotechnology companies can lead you on something of a wild ride.The field, which...

Emergent BioSolutions Inc. (EBS) on Friday said that it has secured new purchase orders from an international government partner for a multiproduct supply agreement.The agreement is valued at $29 million, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-29-million-mcm-product-orders">said</a>. The order encompasses several product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism. The company said that this is the second procurement made by the same government this year.Shares of the company jumped 3% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/EBS">EBS stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:575/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_11_37_08_AM_png_46c276596d.webp" alt="EBS's Sentiment Meter and Message Volume as of 11:37 a.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="575" height="61"><figcaption>EBS's Sentiment Meter and Message Volume as of 11:37 a.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock is “significantly undervalued,” while indicating that they see more than 100% upside.<stembedurl>https://stocktwits.com/NRG8/message/629302236</stembedurl>Another user expects the stock to hit $10 next week.<stembedurl>https://stocktwits.com/shoagh12/message/629291934</stembedurl>Emergent said it will receive about $26 million in 2025 under the agreement. This is in addition to more than $100 million in sales already generated for the company’s MCM portfolio outside the U.S. so far this year, it said.“Together with demand from the U.S. government, these international procurements reinforce the potential for our growth trajectory as part of Emergent’s multi-year transformation plan and highlights the strength of Emergent’s global footprint,” CEO Joe Papa said. The CEO also added that the company continues to see countries elevating their investment in defense preparedness.Emergent delivers solutions for health threats like Smallpox, Mpox, Botulism, Ebola, Anthrax, and Opioid overdose emergencies.Earlier this week, the company also announced that it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply Tembexa oral suspension. At the start of the month, the company also announced that a contract modification had been executed for $56 million to supply ACAM2000, a live vaccinia virus vaccine approved by the FDA for use in preventing Smallpox and Mpox in individuals at high risk of infection, to the U.S. government.EBS stock is down 14% this year but up approximately 17% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-likely-preparing-22to24-per-share-bid-for-warner-bros-discovery/chD34ulR3Ta">Paramount Skydance Likely Preparing $22 To $24 Per Share Bid For Warner Bros. Discovery: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the Emergent BioSolutions logo of an US biopharmaceutical company is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’

The order encompasses multiple product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism.

Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment used for certain complications of the smallpox vaccine, to the U.S. government.The company’s shares closed 3.8% higher at $6.87 on Tuesday, with shares rising another 3.5% to $7.11 in after-hours trading.The new shipment is part of a long-term deal signed back in 2019 with the Administration for Strategic Preparedness and Response, a branch of the Department of Health and Human Services.&nbsp;CNJ-016 is used to treat uncommon but serious side effects from the smallpox vaccine, such as eczema vaccinatum and progressive vaccinia.&nbsp;It is not intended for&nbsp;the treatment of postvaccinal encephalitis or isolated vaccinia keratitis.&nbsp;The product comes with several safety considerations, including risks of allergic reactions, kidney issues, blood clots, and inaccurate blood sugar readings in some patients due to interference with glucose monitors.This latest modification comes shortly after a separate $62.4 million award on June 23, also from ASPR, for additional supply of Emergent’s botulism antitoxin, BAT.&nbsp;The BAT treatment is used in confirmed or suspected cases of botulism involving multiple neurotoxin types.In a separate update last week, the company expanded its NARCANDirect platform to include Kloxxado Nasal Spray 8 mg, an opioid overdose reversal medication.&nbsp;The online ordering system is available to groups, including first responders, schools, government agencies, and community-based programs focused on naloxone distribution.On Stocktwits, retail sentiment was ‘neutral’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/EBS">Emergent BioSolutions’ stock</a> has risen 33.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Emergent BioSolutions Stock Rises After New US Order For Smallpox Complication Therapy

The company also secured a $62.4 million modification to its botulism antitoxin supply contract and recently expanded its NARCANDirect platform to include a new opioid overdose reversal spray.

5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost

Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions

Emergent Biosolutions (EBS) Q1 Earnings Top Estimates

Shares of Emergent BioSolutions plunged more than 8% in after-hours trading on Monday after the company reported a steep revenue drop in the fourth quarter.&nbsp;While Emergent swung to a profit, the earnings beat failed to offset concerns over its shrinking top line.The medical contract development and manufacturing firm posted adjusted net income of $0.05 per diluted share, a sharp reversal from the $0.77 per share loss a year earlier. Analysts had expected a loss of $0.43 per share.&nbsp;However, quarterly revenue fell to $194.7 million from $276.6 million a year ago, well below the consensus estimate of $249.5 million.For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.&nbsp;For 2025, the company projected revenue of $750 million to $850 million, significantly trailing the $1.11 billion analysts had expected.“We delivered favorable full-year financial results driven by our core products, all the while completing a series of strategic stabilization actions to strengthen our financial position ahead of plan,” CEO Joe Papa said.&nbsp;“This strong foundation enables Emergent to focus on profitable revenue growth and cash generation as we move forward with turnaround activities, a critical phase in our multi-year transformation plan.”Despite the revenue shortfall, retail traders on Stocktwits remained optimistic, with sentiment for EBS ending Monday in the ‘bullish’ zone.&nbsp;Many users focused on the company’s improving profitability rather than its shrinking revenue.&nbsp;One trader compared the current situation to a period before Emergent had its Narcan opioid overdose nasal spray in its portfolio, arguing that profitability was the key factor.<stembedurl>https://stocktwits.com/WinstonSmith33/message/606629996</stembedurl>Another user pointed to CEO Joe Papa’s comments on the earnings call, noting that the company’s 2025 guidance appeared “conservative.”&nbsp;<stembedurl>https://stocktwits.com/GrantDiaz/message/606587312</stembedurl>Some traders speculated that Emergent’s mpox vaccine sales had not yet been factored into the guidance.&nbsp;While the company’s smallpox vaccine has been used for mpox, it has not yet&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/govx-siga-ebs-cmrx-stocks-gain-who-declares-who-public-health-emergency/cJId4JgRge">received</a> formal FDA approval for that indication.<a href="https://stocktwits.com/symbol/EBS">Emergent BioSolutions shares</a> are down more than 28% year-to-date but have more than doubled over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.

Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 40%, But Retail Clings To Profit Swing

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.


Shares of GeoVax Labs Inc. (<a class="mention" data-mention="$GOVX" data-symbol-id="GOVX" href="https://stocktwits.com/symbol/GOVX" target="_blank">$GOVX</a>), SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), and Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>) gained in mid-day trading on Friday after the World Health Organisation (WHO) reaffirmed that the ongoing upsurge of mpox remains a public health emergency of international concern (PHEIC).Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus.&nbsp;“The decision was based on the rising number and continuing geographic spread of cases, operational challenges in the field, and the need to mount and sustain a cohesive response across countries and partners,” the apex health agency said in a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WHO/status/1860015125463175343">post</a> on X (formerly Twitter).&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_132250_27d9a22ffc.png" alt="Screenshot 2024-11-22 132250.png">The WHO first declared mpox a PHEIC in August earlier this year because a new strain of the virus, Clade Ib, had spread to countries that had not previously reported any incidences of the disease, like Thailand and Sweden.&nbsp;Shares of GeoVax, currently working on a vaccine for mpox and smallpox, were up nearly 10% in mid-day trading on Friday. The stock has lost 47% of its value this year so far.&nbsp;<stembedurl>https://stocktwits.com/gabbs/message/593724551</stembedurl>Meanwhile, shares of SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), developing an investigational drug for treating mpox called tecovirimat (TPOXX),&nbsp; jumped 2.5% after the news.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134247_8c8f14c041.png" alt="Screenshot 2024-11-22 134247.png">Retail sentiment around the stock improved to ‘bullish’ (60/100) from ‘neutral’ a day ago.&nbsp;SIGA Technologies’ shares have gained 11% this year so far.There was less movement around Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>), also working on a vaccine for mpox, which saw a marginal uptick of 0.6% in mid-day trading on Friday.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134547_d67811671e.png" alt="Screenshot 2024-11-22 134547.png">Retail sentiment around the stock remained in the ‘neutral’ zone with no significant change in chatter.&nbsp;Emergent Biosolutions’ vaccine, approved for smallpox, has also been used as a mpox shot, but the U.S. Food and Drug Administration is yet to approve its application for use against the virus.<stembedurl>https://stocktwits.com/WinstonSmith33/message/593679534</stembedurl>In 2022, the company acquired the rights to a smallpox treatment called Tembexa, which was developed by Chimerix Inc. ($CMRX), for up to $337.5 million plus royalties.Chimerix was up around 0.6% as well during mid-day trading.&nbsp;For updates and corrections email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/agrify-stock-doubles-to-hit-over-1-year-high-after-25-9-m-placement-but-retail-wary-of-short-covering-rally/cJIdTKHRg3">Agrify Stock Doubles To Hit Over 1-Year High After $25.9M Placement, But Retail Wary Of Short-Covering Rally</a>

Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus. | Source: Pexels

GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks

Emergent Biosolutions and Chimerix also saw marginal gains after the announcement. 

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.27	--	--	N/A
Q3 '25	-$0.07	$1.06	1689.99%	BEAT
Q2 '25	-$0.41	$0.16	138.71%	BEAT
Q1 '25	$0.44	$0.71	61.36%	BEAT
Q4 '24	-$0.43	$0.05	111.63%	BEAT

EBS
Emergent Biosolutions Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest EBS News

EBSEmergent Biosolutions Inc